

1

Supporting information

2 **Hyaluronic acid-modified Se@PDA@CDDP nanoplatform for synergistic chemo-**
3 **photothermal therapy and immune activation via redox modulation**

4

5 Yong Huang^{† a}, Hong Hong^{† a}, Lan Xia^a, Lifang Huang^a, Chuqi Shao^a, Manli Qu^a,
6 Wenjun He^a, Suqiong Liang^a, Cunchuan Wang^{*b}, Yanping Qiu^{*c}

7

8 ^aThe Sixth Affiliated Hospital of Jinan University (Dongguan Eastern Central
9 Hospital), Dongguan, Guangdong, 523573, China.

10 ^bThe First Affiliated Hospital of Jinan University, Guangzhou, 510000, China.

11 ^cThe Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital),
12 Heyuan, Guangdong, 517000, China


13

14 [†]These authors contributed equally to the present research.

15 *Corresponding author: twcc@jnu.edu.cn (Cunchuan Wang), quick504@163.com
16 (Yanping Qiu).

17

18



19

20 **Fig S1** Full raw Western blot data of P-P65 and β -actin corresponding to Figure 4. The
 21 samples were derived from the following groups: Control, Control+NIR,
 22 Se@PDA@HA, Se@PDA@HA+NIR, Se@PDA@HA@CDDP, and
 23 Se@PDA@HA@CDDP + NIR. Molecular weight markers are indicated on the left,
 24 and β -actin served as the loading control.